Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Treating Uveitis with Adalimumab Improves Quality of Life

Marilynn Larkin  |  

She concludes, “We need additional studies to give insight into the impact of things like cost of treatment, need for monitoring, and long-term effects of therapy—all of which are important considerations in the treatment of patients with uveitis.”

The study was funded by AbbVie, which markets adalimumab (Humira). Dr. Sheppard has received consulting fees from AbbVie and other companies. Three coauthors are AbbVie employees and own AbbVie stock, and another three have received consulting fees from AbbVie.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017 Apr 20. doi: 10.1001/jamaophthalmol.2017.0603. [Epub ahead of print]
  2. Burkholder BM, Ramulu PY. Improving more than just vision in noninfectious uveitis. JAMA Ophthalmol. 2017 Apr 20. doi: 10.1001/jamaophthalmol.2017.0716. [Epub ahead of print]

Related Articles

    An Overview of Pediatric, Noninfectious Uveitis

    Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…

    Watch Those Eyes

    What you need to know about Uveitis in Rheumatic Diseases

    ARZTSAMUI / shutterstock.com

    Uveitis: A Brief Primer for the Rheumatologist

    Uveitis is an umbrella term for intraocular inflammatory diseases that can lead to vision loss. It’s not just a concern for ophthalmologists. Uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients with reactive arthritis. The prevalence may be as high as 33% in…